BM-32 CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL

BACKGROUND: Ceritinib is an ALK inhibitor (ALKi) recently approved for patients with ALK+ advanced NSCLC. Efficacy and safety were evaluated in a subset of patients with BM in the phase I ASCEND-1 study. In 246 patients with ALK+ NSCLC who received ceritinib 750 mg/day, overall response rate (ORR) w...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Shaw, Alice, Mehra, Ranee, Tan, Daniel S.W., Felip, Enriqueta, Chow, Laura Q.M., Ross Camidge, D., Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey, Santoro, Armando, Geraldes, Margarida, Sen, Paramita, Boral, Anthony J., Yovine, Alejandro, Kim, Dong-Wan
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2014
Assuntos:
Abstracts
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217934/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou240.32
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares